ABSTRACT

A compound of the formula:



(I)

or a pharmaceutically acceptable salt thereof, wherein R^1 is unsubstituted, mono-, di- or tri-substituted (C_3-C_{11})cycloalkyl or (C_3-C_{11})cycloalkenyl or the like, A is unsubstituted (C_1-C_7)alkyl or (C_2-C_5)alkenyl, hydroxy-(C_1-C_4)alkyl, (C_1-C_4)alkoxy-(C=O),or unsubstituted, mono-, di- or tri- substituted aryl, or aromatic-heterocyclic or the like, M is a covalent bond O, S, NH or the like, Y is 4- to 12-membered bicyclic-carbocyclic rings or 4- to 12-membered bicyclic-heterocyclic rings, or 5- to 17 membered spirocarbocyclic rings or 5- to 17-membered spiroheterocyclic rings or the like, Z^1, Z^2, Z^3 and Z^4 are hydrogen or the like, is disclosed. These compounds have ORL1-receptor agonist activity, and are thus useful as analgesics or the like in mammalian subjects.